GlaxoSmithKline files its arguments to Supreme Court of Canada

GlaxoSmithKline (GSK) has filed its case facts with the Supreme Court of Canada refuting arguments made by the Crown in this precedent-setting transfer pricing case, involving the price of the active ingredient used to make the drug sold under the brand name Zantac.

Locked content

The article you are trying to view is only available to subscribers and current trialists